A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT07452198 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

358

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: GR1803 injection
DRUG: Daratumumab
DRUG: Pomalidomide
DRUG: Dexamethasone

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.